Almost all the plaintiffs in 34 federal cases about the blood thinner Eliquis agree with the drugmakers that the actions should be centralized before one judge — now the question is where.
Attorneys for defendants Bristol-Myers Squibb Co. and Pfizer Inc. pushed Thursday to consolidate the cases as multidistrict ligitation in the Southern District of New York. The drug companies both have New York headquarters, and defense attorney Loren Brown of DLA Piper’s New York office told the Judicial Panel on Multidistrict Litigation that witnesses and documents related to the case will come from those headquarters.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
